New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 28, 2013
07:17 EDTVRTXVertex shares should be bought on pullbacks, says RBC Capital
RBC Capital recommends buying Vertex on pullbacks as it thinks the stock could move towards $80+ on positive Phase III CF combo data in 1H14. The firm maintains a $70 price target and Outperform rating on the shares.
News For VRTX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
January 13, 2015
15:22 EDTVRTXVertex CEO says 'way too early' to talk about pricing for new CF combo drug
Vertex CEO Jeff Leiden speaking on CNBC.
07:36 EDTVRTXVertex price target raised to $146 from $125 at Piper Jaffray
Piper Jaffray raised its price target for Vertex Pharmaceuticals shares to $146 citing continued Kalydeco growth after the company issued 2015 guidance. Piper reiterates an Overweight rating on Vertex.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use